

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): ~~A~~An isolated polypeptide which comprises the amino acid sequence represented by SEQ ID NO:2 or 4, and binds to ~~CAP~~ c-Cbl-associated protein (CAP); or ~~a~~ an isolated polypeptide which consists of an amino acid sequence in which 1 to ~~340~~ amino acids are deleted, substituted, and/or inserted in the amino acid sequence represented by SEQ ID NO:2 or 4, and binds to CAP.

2. (currently amended): ~~A~~An isolated polypeptide which consists of an amino acid sequence having a ~~homology~~ sequence identity of ~~90~~98% or more with the amino acid sequence represented by SEQ ID NO:2 or 4, and is a protein which binds to CAP.

3. (currently amended): ~~A~~An isolated polypeptide consisting of the amino acid sequence represented by SEQ ID NO:2 or 4.

4. (withdrawn): A polynucleotide encoding the polypeptide according to any one of claims 1 to 3.

5. (withdrawn): An expression vector comprising the polynucleotide according to claim 4.
6. (withdrawn): A cell transformed with the expression vector according to claim 5.
7. (withdrawn): A method for screening a binding inhibitor between the polypeptide according to any one of claims 1 to 3 and CAP, which comprises:
 - allowing the polypeptide to contact with a test substance,
 - measuring change of binding between the polypeptide and CAP, and
 - selecting a substance which inhibits the binding.
8. (withdrawn): The method for screening according to claim 7, wherein the binding inhibitor is an agent for improving insulin resistance and/or an agent for improving glucose metabolism.
9. (withdrawn): A method for screening an agent for improving insulin resistance and/or an agent for improving glucose metabolism, which comprises:
 - allowing a cell which expresses the polypeptide according to any one of claims 1 to 3 to contact with a test substance, and
 - measuring change of the expression amount of the polypeptide.

10. (withdrawn): A method for producing a pharmaceutical composition for improving insulin resistance and/or improving glucose metabolism, which comprises:

carrying out screening with the method for screening according to any one of claims 7 to 9, and

carrying out formulation using the substance obtained by the screening.

11. (new): The isolated polypeptide according to claim 1, which comprises the amino acid sequence represented by SEQ ID NO:2 or 4, and binds to c-Cbl-associated protein.